PepGen to discontinue development of experimental Duchenne therapy; shares drop

PepGen to discontinue development of experimental Duchenne therapy; shares drop

(Reuters) -Drug developer PepGen said on Wednesday it will discontinue development of its experimental therapy for Duchenne muscular dystrophy (DMD) after it failed to boost production of a protein in a mid-stage study. Shares of the company were down 9.5% at $1.43 in extended trading. The therapy PGN-EDO51 did not achieve target levels of dystrophin production. Dystrophin is a protein whose absence leads to muscle weakening in patients with DMD…

PepGen ditches Duchenne programs after mid-stage fail, switches to previously halted muscle wasting therapy

PepGen is abandoning its exon 51-skipping Duchenne muscular dystrophy candidate after it failed a Phase 2 trial. And it is getting out of the disease altogether as it discards three preclinical programs as well. ...

Newport Beach-Based CureDuchenne Appoints Brenda Wong, MD, as Chief Medical Advisor - Newport Beach News

Brenda Wong, MD CureDuchenne, a global nonprofit based in Newport Beach committed to finding and funding a cure for Duchenne muscular dystrophy, has announced the appointment of Brenda Wong, MD, as its new Chief Medical Advisor, effective January 5, 2026. A nationally recognized authority in neuromuscular medicine and clinical research, Dr. Wong has devoted her career to compassionate, patient-centered care for those living with Duchenne and Bec…

PepGen ends development of Duchenne Exon-51 skipping program

PepGen has ended clinical trials of PGN-EDO51, their investigational therapy for Duchenne patients amenable to skipping exon 51, as PGN-EDO51 failed to achieve target dystrophin levels in their CONNECT1 trial. The company intends to wind down all DMD-related research and development activities. While it is a disappointing outcome, we’d like to thank PepGen, who CureDuchenne provided early funding to, for their work developing PGN-EDO51 and tryin…